```
=> b reg
FILE 'REGISTRY' ENTERED AT 17:31:12 ON 12 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 MAR 2008  HIGHEST RN 1007457-12-6
DICTIONARY FILE UPDATES:  11 MAR 2008  HIGHEST RN 1007457-12-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l7
L5              STR
```




```
REP G1=(0-2) C
REP G2=(0-4) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L7          763 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED   53150 ITERATIONS                          763 ANSWERS
SEARCH TIME: 00.00.02



=> b hcap
FILE 'HCAPLUS' ENTERED AT 17:31:21 ON 12 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
```

FILE COVERS 1907 - 12 Mar 2008 VOL 148 ISS 11
FILE LAST UPDATED: 11 Mar 2008 (20080311/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitstr l14 tot

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:192244 HCAPLUS
TI Preparation of pyridazinonyl macrocyclic peptides as hepatitis C serine protease inhibitors
IN Moore, Joel D.; Tang, Datong; Or, Yat Sun; Wang, Zhe
PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 94pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO--2008019303 | A2 | 20080214 | 2007WO-US075146 | 20070803 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI 2006US-000499844 | A | 20060804 | | |
| 2007US-000832893 | A | 20070802 | | |

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to macrocyclic compds. I [A = COOR1, COR2, CONR1R2, SO2R1, SO2NR1R2; R1 = (un)substituted (hetero)aryl, heterocycloalkyl, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S or N; cycloalk(en)yl; R2 = H, R1; G = NHSO2R3, R3 = R1 provided that R3 is not CH2Ph or CH2CH2Ph; R4, R5 = independently any of R2; L = CH2, O, S, SO2; X, Y, Z = independently H, CN, N3, OH and derivs., NH2 and derivs., (un)substituted (hetero)aryl, etc.; or XCCY or YCCZ = (un)substituted (hetero)aromatic ring; B = (CH2)j; j = 0-4; D = (CH2)k; k = 1-3; U = (CH2)m; m = 0-2; T = (CH2)n; n = 1-3] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, macrocycle II was prepared via peptide coupling and ring-closing metathesis reactions. Representative compds. of the invention were found to have HCV activity in the ranges of 0.2 nM - 100 nM in the NS3/NS4A protease enzyme assay and 0.2 nM - 1000 nM in the cell based replicon assay.

IT 1007094-86-1P 1007094-87-2P 1007094-88-3P
1007094-90-7P
RL: BYP (Byproduct); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridazinonyl macrocyclic peptides as hepatitis C serine protease inhibitors)

IT 1007094-76-9P 1007094-82-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyridazinonyl macrocyclic peptides as hepatitis C serine protease inhibitors)

IT 1007094-62-3P 1007094-63-4P 1007094-64-5P
1007094-65-6P 1007094-66-7P 1007094-67-8P
1007094-68-9P 1007094-69-0P 1007094-70-3P
1007094-71-4P 1007094-72-5P 1007094-73-6P
1007094-74-7P 1007094-75-8P 1007094-77-0P
1007094-78-1P 1007094-79-2P 1007094-80-5P

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
1007094-81-6P 1007094-83-8P 1007094-84-9P
1007094-85-0P 1007094-89-4P 1007094-91-8P
1007094-93-0P 1007094-94-1P 1007094-95-2P
1007094-96-3P 1007094-97-4P 1007094-98-5P
1007094-99-6P 1007095-00-2P 1007095-01-3P
1007095-02-4P 1007095-03-5P 1007095-04-6P
1007095-05-7P 1007095-06-8P 1007095-07-9P
1007095-08-0P 1007095-09-1P 1007095-10-4P
1007095-11-5P 1007095-12-6P 1007095-13-7P
1007095-14-8P 1007095-15-9P 1007095-16-0P
1007095-18-2P 1007095-25-1P 1007095-27-3P
1007095-29-5P 1007095-31-9P 1007095-33-1P
1007095-35-3P 1007095-37-5P 1007095-38-6P
1007095-41-1P 1007095-43-3P 1007095-45-5P
1007095-47-7P 1007095-49-9P 1007095-51-3P
1007095-53-5P 1007095-54-6P 1007095-55-7P
1007095-56-8P 1007095-57-9P 1007095-58-0P
1007095-59-1P 1007095-60-4P 1007095-61-5P
1007095-62-6P 1007095-63-7P 1007095-64-8P
1007095-65-9P 1007095-66-0P 1007095-67-1P
1007095-68-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridazinonyl macrocyclic peptides as hepatitis C serine protease inhibitors)

IT 1007095-70-6P 1007095-71-7P 1007095-72-8P
1007095-73-9P 1007095-74-0P 1007095-75-1P
1007095-76-2P 1007095-78-4P 1007095-79-5P
1007095-80-8P 1007095-81-9P 1007095-82-0P
1007095-83-1P 1007095-84-2P 1007095-85-3P
1007095-86-4P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridazinonyl macrocyclic peptides as hepatitis C serine protease inhibitors)

IT 744249-42-1P 744249-43-2P 744249-44-3P
744249-45-4P 744249-46-5P 744249-47-6P
744249-49-8P 744249-50-1P 744249-52-3P
744249-53-4P 744249-54-5P 744249-56-7P
744249-59-0P 744249-60-3P 744249-65-8P
744249-68-1P 1007094-60-1P 1007094-61-2P
1007096-59-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridazinonyl macrocyclic peptides as hepatitis C serine protease inhibitors)

IT 1007094-86-0P
RL: BYP (Byproduct); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridazinonyl macrocyclic peptides as hepatitis C serine protease inhibitors)

RN 1007094-86-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:192063 HCAPLUS
TI Preparation of tetrazolyl macrocyclic peptides as hepatitis C serine protease inhibitors
IN Sun, Ying; Liu, Dong; Or, Yat Sun; Wang, Zhe
PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 100pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO--2008019289 | A2 | 20080214 | 2007WO-US075066 | 20070802 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI 2006US-000499245 | A | 20060804 | | |
| 2007US-000832240 | A | 20070801 | | |

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to macrocyclic compds. I, II, III and IV [A = R1, COOR1, COR2, CONHR2, SO2R1, SO2NHR2; R1 = (un)substituted (hetero)aryl, heterocycloalkyl, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S or N, cycloalk(en)yl; R2 = H, R1; G = NHSO2R3, NHSO2NR4R5; R3 = R1 provided that R3 is not CH2Ph or CH2CH2Ph; R4, R5 = independently any of R2; L = CH2, O, S, SO2; X = H, R1, WR2; W = absent, O, S, NH, NMe, CONH, CONMe; B = (CH2)j; j = 0-4; D = (CH2)k; k = 1-3; U = (CH2)m; m = 0-2; T = (CH2)n; n = 1-3] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, macrocycle V was prepared via peptide coupling and ring-closing metathesis reactions. Representative compds. of the invention were found to have HCV activity in the ranges of 0.2 nM - 100 nM in the NS3/NS4A protease enzyme assay and 0.2 nM - 1000 nM in the cell based replicon assay. Pharmacokinetic anal. of representative compds. showed high liver drug levels. These compds. did not exhibit any significant inhibitions of Cytochrome P 450 enzymes.

IT 1007127-41-4P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrazolyl macrocyclic peptides as hepatitis C serine protease inhibitors)

IT 1007127-18-5P 1007127-19-6P 1007127-20-9P
1007127-21-0P 1007127-22-1P 1007127-23-2P
1007127-24-3P 1007127-25-4P 1007127-26-5P
1007127-27-6P 1007127-28-7P 1007127-29-8P
1007127-30-1P 1007127-31-2P 1007127-32-3P
1007127-33-4P 1007127-35-6P 1007127-36-7P
1007127-37-8P 1007127-38-9P 1007127-40-3P
1007127-42-5P 1007127-43-6P 1007127-44-7P
1007127-45-8P 1007127-46-9P 1007127-47-0P
1007127-48-1P 1007127-49-2P 1007127-50-5P
1007127-51-6P 1007127-52-7P 1007127-53-8P
1007127-54-9P 1007127-55-0P 1007127-56-1P
1007127-57-2P 1007127-59-4P 1007127-60-7P
1007127-61-8P 1007127-62-9P 1007127-63-0P
1007127-64-1P 1007127-65-2P 1007127-66-3P
1007127-67-4P 1007127-68-5P 1007127-69-6P

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

1007127-70-9P 1007127-71-0P 1007127-72-1P
1007127-73-2P 1007127-74-3P 1007127-75-4P
1007127-76-5P 1007127-77-6P 1007127-78-7P
1007127-79-8P 1007127-80-1P 1007127-81-2P
1007127-82-3P 1007127-83-4P 1007127-84-5P
1007127-85-6P 1007127-86-7P 1007127-87-8P
1007127-88-9P 1007127-89-0P 1007127-90-3P
1007127-91-4P 1007127-93-6P 1007127-95-8P
1007127-97-0P 1007127-98-1P 1007127-99-2P
1007128-00-8P 1007128-01-9P 1007128-02-0P
1007128-03-1P 1007128-04-2P 1007128-06-4P
1007128-07-5P 1007128-09-7P 1007128-10-0P
1007128-12-2P 1007128-13-3P 1007128-15-5P
1007128-16-6P 1007128-17-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrazolyl macrocyclic peptides as hepatitis C serine protease inhibitors)

IT 1007128-26-8P 1007128-31-5P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrazolyl macrocyclic peptides as hepatitis C serine protease inhibitors)

IT 744247-24-3P 744247-28-7P 744247-34-5P
744247-68-5P 744247-82-3P 744248-03-1P
744248-06-4P 744248-18-8P 744248-30-4P
744248-36-0P 744249-96-5P 744250-03-1P
1007127-92-5P 1007127-94-7P 1007127-96-9P
1007128-05-3P 1007128-08-6P 1007128-11-1P
1007128-14-4P 1007128-21-3P 1007128-32-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrazolyl macrocyclic peptides as hepatitis C serine protease inhibitors)

IT 1007127-41-4P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrazolyl macrocyclic peptides as hepatitis C serine protease inhibitors)

RN 1007127-41-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:611823 HCAPLUS
DN 143:153709
TI Synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors
IN Miao, Zhenwei; Sun, Ying; Nakajima, Suanne; Tang, Datong; Wu, Frank; Xu, Guoyou; Or, Yat S.; Wang, Zhe
PA USA
SO U.S. Pat. Appl. Publ., 229 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US--2005153877 | A1 | 20050714 | 2004US-000774047 | 20040206 |
| PRAI 2003US-00509069P | P | 20030213 | | |

OS MARPAT 143:153709
GI



I

AB The invention relates to cyclic peptides I [A = H, COR2, CO2R1, CONHR2, etc.; G = OH, alkoxy, NHSO2R1, CO2R1, CONHR1, etc.; L = absent, S, SO2, O, COCH2, CF2CH2, etc.; j = 0-4; m, s = 0-2; R1,R2 = H, C1-6-alkyl, (substituted)aryl, heteroaryl, etc.; R3,R4 = H, OH, Me, CN, SH, halo, NO2, NH2, amide, MeO, CF3O, CF3; E = CH:CH, CH2CH2; W = (un)substituted heterocyclic ring], or their pharmaceutically-acceptable salts, esters, or prodrugs, which inhibit serine protease activity, particularly the activity of HCV NS3-NS4A protease. An example is I (A = Me3CO2C, G = OH, L = absent, W = 5-phenyl-1,2,3,4-tetrazol-2-yl, j = 3, m, s = 1; R3, R4 = H), which was prepared via peptide coupling and ring-closing metathesis.

IT 744247-19-6P 744247-22-1P 744247-24-3P
744247-26-5P 744247-28-7P 744247-30-1P
744247-32-3P 744247-34-5P 744247-36-7P
744247-38-9P 744247-40-3P 744247-42-5P
744247-44-7P 744247-46-9P 744247-48-1P
744247-50-5P 744247-52-7P 744247-54-9P
744247-56-1P 744247-58-3P 744247-60-7P
744247-62-9P 744247-64-1P 744247-66-3P
744247-68-5P 744247-70-9P 744247-72-1P
744247-74-3P 744247-76-5P 744247-78-7P
744247-80-1P 744247-82-3P 744247-84-5P
744247-86-7P 744247-88-9P 744247-91-4P
744247-94-7P 744247-97-0P 744248-00-8P
744248-03-1P 744248-06-4P 744248-09-7P
744248-12-2P 744248-15-5P 744248-18-8P
744248-20-2P 744248-22-4P 744248-24-6P
744248-26-8P 744248-28-0P 744248-30-4P
744248-32-6P 744248-34-8P 744248-36-0P
744248-38-2P 744248-40-6P 744248-42-8P
744248-44-0P 744248-45-1P 744248-46-2P
744248-47-3P 744248-48-4P 744248-49-5P
744248-50-8P 744248-52-0P 744248-53-1P
744248-55-3P 744248-58-6P 744248-59-7P
744248-60-0P 744248-67-7P 744248-68-8P
744248-69-9P 744248-70-2P 744248-71-3P
744248-72-4P 744248-73-5P 744248-74-6P
744248-75-7P 744248-76-8P 744248-77-9P

L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

744248-78-0P 744248-79-1P 744248-80-4P
744248-81-5P 744248-82-6P 744248-83-7P
744248-84-8P 744248-85-9P 744248-86-0P
744248-87-1P 744248-88-2P 744248-89-3P
744248-90-6P 744248-91-7P 744248-92-8P
744248-93-9P 744248-94-0P 744248-95-1P
744248-96-2P 744248-97-3P 744249-00-1P
744249-04-5P 744249-07-8P 744249-11-4P
744249-14-7P 744249-16-9P 744249-19-2P
744249-22-7P 744249-24-9P 744249-26-1P
744249-27-2P 744249-33-0P 744249-34-1P
744249-35-2P 744249-36-3P 744249-37-4P
744249-38-5P 744249-39-6P 744249-40-9P
744249-41-0P 744249-42-1P 744249-43-2P
744249-44-3P 744249-45-4P 744249-46-5P
744249-47-6P 744249-48-7P 744249-49-8P
744249-50-1P 744249-51-2P 744249-52-3P
744249-53-4P 744249-54-5P 744249-55-6P
744249-56-7P 744249-57-8P 744249-58-9P
744249-59-0P 744249-60-3P 744249-61-4P
744249-62-5P 744249-63-6P 744249-64-7P
744249-65-8P 744249-66-9P 744249-67-0P
744249-68-1P 744249-69-2P 744249-70-5P
744249-71-6P 744249-72-7P 744249-73-8P
744249-74-9P 744249-75-0P 744249-76-1P
744249-77-2P 744249-78-3P 744249-84-1P
744249-85-2P 744249-86-3P 744249-87-4P
744249-88-5P 744249-89-6P 744249-90-9P
744249-91-0P 744249-92-1P 744249-93-2P
744249-94-3P 744249-95-4P 744249-96-5P
744249-97-6P 744249-98-7P 744249-99-8P
744250-00-8P 744250-01-9P 744250-02-0P
744250-03-1P 744250-04-2P 744250-05-3P
744250-06-4P 744250-07-5P 744250-08-6P
744250-09-7P 744250-10-0P 744250-11-1P
744250-12-2P 744250-13-3P 744250-14-4P
744250-15-5P 744250-16-6P 744250-17-7P
744250-18-8P 744250-19-9P 744250-20-2P
744250-21-3P 744250-22-4P 744250-23-5P
744250-24-6P 744250-25-7P 744250-26-8P
744250-27-9P 744250-28-0P 744250-29-1P
744250-30-4P 744250-31-5P 744250-32-6P
744250-33-7P 744250-34-8P 744250-35-9P
744250-36-0P 744250-37-1P 744250-38-2P
744250-39-3P 744250-40-6P 744250-41-7P
744250-42-8P 744250-43-9P 744250-44-0P
744250-45-1P 744250-46-2P 744250-47-3P
744250-48-4P 744250-49-5P 744250-50-8P
744250-51-9P 744250-52-0P 744250-53-1P
744250-54-2P 744250-55-3P 744250-56-4P
744250-57-5P 744250-58-6P 744250-59-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)

IT 744250-60-0P 744250-61-1P 744250-62-2P
744250-63-3P 744250-64-4P 744250-65-5P
744250-66-6P 744250-67-7P 745013-11-0P
746657-33-0P 746657-34-1P 746657-35-2P
858948-81-9P 858948-82-0P 858948-83-1P
858948-84-2P 858948-85-3P 858948-86-4P
858948-87-5P 858948-88-6P 858948-89-7P
858948-90-0P 858948-91-1P 858948-92-2P
858948-93-3P 858948-94-4P 858948-95-5P
858948-96-6P 858948-97-7P 858948-98-8P
858948-99-9P 858949-00-5P 858949-01-6P
858949-02-7P 858949-03-8P 858949-04-9P
858949-05-0P 858949-06-1P 858949-07-2P
858949-08-3P 858949-09-4P 858949-10-7P
858949-11-8P 858949-12-9P 858949-13-0P
858949-14-1P 858949-15-2P 858949-16-3P
858949-17-4P 858949-18-5P 858949-19-6P
858949-20-9P 858949-21-0P 858949-22-1P

L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
858949-23-2P 858949-24-3P 858949-25-4P
858949-26-5P 858949-27-6P 858949-28-7P
858949-29-8P 858949-30-1P 858949-31-2P
858949-32-3P 858949-33-4P 858949-34-5P
858949-35-6P 858949-36-7P 858949-37-8P
858949-38-9P 858949-39-0P 858949-40-3P
858949-41-4P 858949-42-5P 858949-43-6P
858949-44-7P 858949-45-8P 858949-46-9P
858949-47-0P 858949-48-1P 858949-49-2P
858949-50-5P 858949-53-8P 858949-54-9P
858949-55-0P 858949-56-1P 858949-57-2P
858949-58-3P 858949-59-4P 858949-60-7P
858949-61-8P 858949-62-9P 858949-63-0P
858949-64-1P 858949-66-3P 858949-67-4P
858949-68-5P 858949-69-6P 858949-70-9P
858949-71-0P 858949-72-1P 858949-73-2P
858949-74-3P 858949-75-4P 858949-76-5P
858949-77-6P 858949-78-7P 858949-79-8P
858949-80-1P 858949-81-2P 858949-82-3P
858949-83-4P 858949-84-5P 858949-85-6P
858949-86-7P 858949-87-8P 858949-88-9P
858949-89-0P 858949-90-3P 858949-91-4P
858949-92-5P 858949-93-6P 858949-96-9P
858949-97-0P 858949-98-1P 858949-99-2P
858950-00-2P 858950-01-3P 858950-02-4P
858950-03-5P 858950-04-6P 858950-05-7P
858950-06-8P 858950-07-9P 858950-08-0P
858950-09-1P 858950-10-4P 858950-11-5P
858950-12-6P 858950-13-7P 858950-14-8P
858950-15-9P 858950-16-0P 858950-17-1P
858950-18-2P 858950-19-3P 858950-20-6P
858950-21-7P 858950-22-8P 858950-23-9P
858950-24-0P 858950-25-1P 858950-26-2P
858950-27-3P 858950-28-4P 858950-29-5P
858950-30-8P 858950-31-9P 858950-32-0P
858950-33-1P 858950-35-3P 858950-37-5P
858950-39-7P 858950-41-1P 858950-42-2P
858950-45-5P 858950-57-9P 858950-58-0P
858950-59-1P 858950-60-4P 858950-61-5P
858950-63-7P 858950-65-9P 858950-66-0P
858950-67-1P 858950-68-2P 858950-69-3P
858950-70-6P 858950-71-7P 858950-72-8P
858950-73-9P 858950-74-0P 858950-75-1P
858950-76-2P 858950-77-3P 858950-78-4P
858950-79-5P 858950-80-8P 858950-81-9P
858950-82-0P 858950-83-1P 858950-84-2P
858950-85-3P 858950-86-4P 858950-87-5P
858950-88-6P 858950-89-7P 858950-90-0P
858950-91-1P 858950-92-2P 858950-93-3P
858950-94-4P 858950-95-5P 858950-96-6P
858950-97-7P 858950-98-8P 858950-99-9P
858951-00-5P 858951-01-6P 858951-02-7P
858951-03-8P 858951-04-9P 858951-05-0P
858951-06-1P 858951-07-2P 858951-08-3P
858951-10-7P 858951-12-9P 858951-13-0P
858951-14-1P 858951-15-2P 858951-16-3P
858951-17-4P 858951-18-5P 858951-19-6P
858951-20-9P 858951-21-0P 858951-22-1P
858951-23-2P 858951-24-3P 858951-25-4P
858951-26-5P 858951-27-6P 858951-28-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)
IT 858951-29-8P 858951-30-1P 858951-31-2P
858951-32-3P 858951-33-4P 858951-34-5P
858951-35-6P 858951-36-7P 858951-37-8P
858951-38-9P 858951-39-0P 858951-40-3P
858951-41-4P 858951-42-5P 858951-43-6P

L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
858951-44-7P 858951-45-8P 858951-46-9P
858951-47-0P 858951-48-1P 858951-49-2P
858951-50-5P 858951-51-6P 858951-52-7P
858951-53-8P 858951-54-9P 858951-55-0P
858951-56-1P 858951-57-2P 858951-58-3P
858951-59-4P 858951-60-7P 858951-61-8P
858951-62-9P 858951-63-0P 858951-64-1P
858951-65-2P 858951-66-3P 858951-67-4P
858951-68-5P 858951-70-9P 858951-71-0P
858951-72-1P 858951-73-2P 858951-74-3P
858951-75-4P 858951-76-5P 858951-77-6P
858951-78-7P 858951-79-8P 858951-80-1P
858951-81-2P 858951-82-3P 858951-83-4P
858951-84-5P 858951-85-6P 858951-86-7P
858951-87-8P 858951-88-9P 858951-89-0P
858951-90-3P 858951-91-4P 858951-92-5P
858951-93-6P 858951-94-7P 858972-57-3P
858972-58-4P 858972-62-0P 858972-63-1P
858972-64-2P 858972-68-6P 858972-69-7P
858972-70-0P 858972-74-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)
IT 744251-08-9P 744251-12-5P 744251-15-8P
744251-18-1P 744251-21-6P 744251-25-0P
744251-32-9P 744251-33-0P 744251-47-6P
744251-51-2P 744251-52-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)
IT 744247-19-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)
RN 744247-19-6 HCAPLUS
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(5-phenyl-2H-tetrazol-2-yl)-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)




L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:698218 HCAPLUS
DN 141:220883
TI Macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection
IN Miao, Zenwei; Sun, Ying; Wu, Frank; Nakajima, Suanne; Xu, Guoyou; Or, Yat Sun; Wang, Zhe
PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 299 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO--2004072243 | A2 | 20040826 | 2004WO-US00003479 | 20040206 |
| WO--2004072243 | A3 | 20051103 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US--2004180815 | A1 | 20040916 | 2003US-000384120 | 20030307 |
| AU--2004211637 | A1 | 20040826 | 2004AU-000211637 | 20040206 |
| CA-----2515216 | A1 | 20040826 | 2004CA-002515216 | 20040206 |
| EP-----1590442 | A2 | 20051102 | 2004EP-000709020 | 20040206 |
| EP-----1590442 | A3 | 20051221 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN-----1771050 | A | 20060510 | 2004CN-080009268 | 20040206 |
| JP---2007524576 | T | 20070830 | 2006JP-000503381 | 20040206 |
| PRAI 2003US-000360947 | A | 20030207 | | |
| 2003US-000365854 | A | 20030213 | | |
| 2003US-000384120 | A | 20030307 | | |
| 2003US-00509069P | P | 20030213 | | |
| 2004WO-US0003479 | A | 20040206 | | |

OS MARPAT 141:220883
GI




I

AB The present invention relates to compds. I [A = H, COR2, COOR1, CONHR2, etc.; G = OH, COR2, COOR1, CONHR1, etc.; L = S, SO2, O, COCH2, CF2CH2, etc.; j = 0-4; m, s = 0-2; R1,R2 = H, C1-6-alkyl, (substituted)aryl, heteroaryl, etc.; R3,R4 = H, OH, Me, CN, SH, halo, NO2, NH2, amide, MeO, CF3O, CF3; E = CH:CH, CH2CH2; W = (un)substituted heterocyclic ring], or a pharmaceutically acceptable salt, ester, or prodrug thereof, and to methods for their synthesis. The compds. inhibit serine protease activity, particularly the activity of HCV NS3-NS4A protease. Consequently, the compds. of the present invention interfere with the life cycle of HCV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention.

L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 744247-19-6P 744247-22-1P 744247-24-3P
744247-26-5P 744247-28-7P 744247-30-1P
744247-32-3P 744247-34-5P 744247-36-7P
744247-38-9P 744247-40-3P 744247-42-5P
744247-44-7P 744247-46-9P 744247-48-1P
744247-50-5P 744247-52-7P 744247-54-9P
744247-56-1P 744247-58-3P 744247-60-7P
744247-62-9P 744247-64-1P 744247-66-3P
744247-68-5P 744247-70-9P 744247-72-1P
744247-74-3P 744247-76-5P 744247-78-7P
744247-80-1P 744247-82-3P 744247-84-5P
744247-86-7P 744247-88-9P 744247-91-4P
744247-94-7P 744247-97-0P 744248-00-8P
744248-03-1P 744248-06-4P 744248-09-7P
744248-12-2P 744248-15-5P 744248-18-8P
744248-20-2P 744248-22-4P 744248-24-6P
744248-26-8P 744248-28-0P 744248-30-4P
744248-32-6P 744248-34-8P 744248-36-0P
744248-38-2P 744248-40-6P 744248-42-8P
744248-44-0P 744248-45-1P 744248-46-2P
744248-47-3P 744248-48-4P 744248-49-5P
744248-50-8P 744248-52-0P 744248-53-1P
744248-55-3P 744248-58-6P 744248-59-7P
744248-60-0P 744248-67-7P 744248-68-8P
744248-69-9P 744248-70-2P 744248-71-3P
744248-72-4P 744248-73-5P 744248-74-6P
744248-75-7P 744248-76-8P 744248-77-9P
744248-78-0P 744248-79-1P 744248-80-4P
744248-81-5P 744248-82-6P 744248-83-7P
744248-84-8P 744248-85-9P 744248-86-0P
744248-87-1P 744248-88-2P 744248-89-3P
744248-90-6P 744248-91-7P 744248-92-8P
744248-93-9P 744248-94-0P 744248-95-1P
744248-96-2P 744248-97-3P 744249-00-1P
744249-04-5P 744249-07-8P 744249-11-4P
744249-14-7P 744249-16-9P 744249-19-2P
744249-22-7P 744249-24-9P 744249-26-1P
744249-27-2P 744249-33-0P 744249-34-1P
744249-35-2P 744249-36-3P 744249-37-4P
744249-38-5P 744249-39-6P 744249-40-9P
744249-41-0P 744249-42-1P 744249-43-2P
744249-44-3P 744249-45-4P 744249-46-5P
744249-47-6P 744249-48-7P 744249-49-8P
744249-50-1P 744249-51-2P 744249-52-3P
744249-53-4P 744249-54-5P 744249-55-6P
744249-56-7P 744249-57-8P 744249-58-9P
744249-59-0P 744249-60-3P 744249-61-4P
744249-62-5P 744249-63-6P 744249-64-7P
744249-65-8P 744249-66-9P 744249-67-0P
744249-68-1P 744249-69-2P 744249-70-5P
744249-71-6P 744249-72-7P 744249-73-8P
744249-74-9P 744249-75-0P 744249-76-1P
744249-77-2P 744249-78-3P 744249-84-1P
744249-85-2P 744249-86-3P 744249-87-4P
744249-88-5P 744249-89-6P 744249-90-9P
744249-91-0P 744249-92-1P 744249-93-2P
744249-94-3P 744249-95-4P 744249-96-5P
744249-97-6P 744249-98-7P 744249-99-8P
744250-00-8P 744250-01-9P 744250-02-0P
744250-03-1P 744250-04-2P 744250-05-3P
744250-06-4P 744250-07-5P 744250-08-6P
744250-09-7P 744250-10-0P 744250-11-1P
744250-12-2P 744250-13-3P 744250-14-4P
744250-15-5P 744250-16-6P 744250-17-7P
744250-18-8P 744250-19-9P 744250-20-2P
744250-21-3P 744250-22-4P 744250-23-5P
744250-24-6P 744250-25-7P 744250-26-8P
744250-27-9P 744250-28-0P 744250-29-1P
744250-30-4P 744250-31-5P 744250-32-6P
744250-33-7P 744250-34-8P 744250-35-9P
744250-36-0P 744250-37-1P 744250-38-2P
744250-39-3P 744250-40-6P 744250-41-7P
744250-42-8P 744250-43-9P 744250-44-0P
744250-45-1P 744250-46-2P 744250-47-3P

L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
744250-48-4P 744250-49-5P 744250-50-8P
744250-51-9P 744250-52-0P 744250-53-1P
744250-54-2P 744250-55-3P 744250-56-4P
744250-57-5P 744250-58-6P 744250-59-7P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)
IT 744250-60-0P 744250-61-1P 744250-62-2P
744250-63-3P 744250-64-4P 744250-65-5P
744250-66-6P 744250-67-7P 745013-11-0P
746657-33-0P 746657-34-1P 746657-35-2P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)
IT 744251-08-9P 744251-12-5P 744251-15-8P
744251-18-1P 744251-21-6P 744251-25-0P
744251-32-9P 744251-33-0P 744251-47-6P
744251-51-2P 744251-52-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)
IT 744247-19-6P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)
RN 744247-19-6 HCAPLUS
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(5-phenyl-2H-tetrazol-2-yl)-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)



=> d bib abs hitrn fhitstr l13 tot

L13 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:188969 HCAPLUS

TI Preparation of phosphorus-containing peptides as hepatitis C serine protease inhibitors

IN Moore, Joel D.; Niu, Deqiang; Xu, Guoyou; Liu, Dong; Or, Yat Sun; Waug, Zhe

PA USA

SO U.S. Pat. Appl. Publ., 171pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI US--2008039375 | A1 | 20080214 | 2006US-000503407 | 20060811 |
| PRAI 2006US-000503407 | | 20060811 | | |

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to phosphorus-containing peptides I and II [A = COOR1, COR2, CONHR2, SO2R1, SO2NHR2; R1 = (un)substituted (hetero)aryl, heterocycloalkyl, alk(en)yl, alkynyl containing 0-3 heteroatoms selected from O, S or N, cycloalk(en)yl; R2 = H, R1; L = aryl, (un)substituted alk(en)yl, alkynyl containing 0-3 heteroatoms selected from O, S or N, cycloalk(en)yl, heterocyclyl; X = absent, O, S, NR2; Y = absent, (un)substituted alk(en/yn)ylene containing 0-3 heteroatoms selected from O, S or N, (hetero)cycloalkylene; Z = (un)substituted (hetero)aryl; Q = H, SR1, (un)substituted heterocyclyl, cyclo/alkyl, etc.; W = CH2, O, S, SO2, CO, COO, CONH, CHF, CF2, (un)substituted (hetero)arylene; U, V = independently R1, XR2; or UPV = phosphorus-derived heterocyclic moiety; J = (CH2)j; j = 0-4; B = (CH2)k; k = 1-3; G = (CH2)s; s = 0-3; D = (CH2)m; m = 0-2; T = (CH2)n; n = 1-3] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease (no data). The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, macrocycle III was prepared via peptide coupling, ring-closing metathesis and reaction with diphenylphosphinamide. Representative compds. of the invention showed biol. activity in enzyme inhibition and cell-based replicon assays for HCV activity (no data).

IT 1006902-80-2P 1006902-81-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phosphorus-containing peptides as hepatitis C serine protease inhibitors)

IT 1006902-80-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phosphorus-containing peptides as hepatitis C serine protease inhibitors)

RN 1006902-80-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



L13 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



L13 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:186295 HCAPLUS

TI Preparation of acylaminoheteroaryl peptides as hepatitis C serine protease inhibitors

IN Niu, Deqiang; Moore, Joel D.; Liu, Dong; Gai, Yonghua; Chen, Zhigang; Or, Yat Sun; Wang, Zhe

PA USA

SO U.S. Pat. Appl. Publ., 57pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI US--2008039470 | A1 | 20080214 | 2006US-000503502 | 20060811 |
| WO--2008021956 | A2 | 20080221 | 2007WO-US075580 | 20070809 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI 2006US-000503502 | A | 20060811 | | |

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to peptides I and II [A = H, COOR1, COR2, CONHR2, SO2R1, SO2NHR2; R1 = (un)substituted (hetero)aryl, heterocycloalkyl, alk(en)yl, alkynyl containing 0-3 heteroatoms selected from O, S or N, cycloalk(en)yl; R2 = H, R1; R0 = H, Me, Et, OH, CONH2; U, U1, U2 = independently CR3, N; R3 = H, halo, NO2, CN, aryl, etc.; W, V = independently H, or any of R2; X = absent, O, S, NR2; Y = absent, (un)substituted alk(en/yn)ylene containing 0-3 heteroatoms selected from O, S or N, (hetero)cycloalkylene; Z = (un)substituted (hetero)aryl; L = (CH2)j; j = 0-4; Q = (CH2)k; k = 1-3; D = (CH2)m; m = 0-2; T = (CH2)n; n = 1-2] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease (no data). The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, quinoxalinyl macrocycle III was prepared by reaction of alc. IV (preparation given) with 3-(thiophen-2-yl)-1H-quinoxalin-2-one under Mitsunobu conditions, cleavage of the tert-butoxycarbonyl group, treatment with cyclopentyl chloroformate, saponification of the Et ester and coupling of the acid with 5-aminotetrazole. Representative compds. of the invention showed biol. activity in enzyme inhibition and cell-based replicon assays for HCV activity (no data).

IT 1007204-96-7P 1007205-11-9P 1007205-12-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminoheteroaryl peptides as hepatitis C serine protease inhibitors)

IT 1007204-96-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminoheteroaryl peptides as hepatitis C serine protease inhibitors)

RN 1007204-96-7 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

L13 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 17:32:07 ON 12 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:32:07 ON 12 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:32:07 ON 12 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l16 tot
```

L16 ANSWER 1 OF 2 USPATFULL on STN

AN 2005:177796 USPATFULL
TI Macrocyclic hepatitis C serine protease inhibitors
IN Miao, Zhenwei, San Diego, CA, UNITED STATES
Sun, Ying, Waltham, MA, UNITED STATES
Nakajima, Suanne, Cambridge, MA, UNITED STATES
Tang, Datong, Malden, MA, UNITED STATES
Wu, Frank, Shrewsbury, MA, UNITED STATES
Xu, Guoyou, Auburndale, MA, UNITED STATES
Or, Yat S., Watertown, MA, UNITED STATES
Wang, Zhe, Hockessin, DE, UNITED STATES
PI US-20050153877 A1 20050714
AI 2004US-000774047 A1 20040206 (10)
PRAI 2003US-000509069P 20030213 (60)
DT Utility
FS APPLICATION
LREP EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR1## wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 744247-19-6P 744247-22-1P 744247-24-3P
744247-26-5P 744247-28-7P 744247-30-1P
744247-32-3P 744247-34-5P 744247-36-7P
744247-38-9P 744247-40-3P 744247-42-5P
744247-44-7P 744247-46-9P 744247-48-1P
744247-50-5P 744247-52-7P 744247-54-9P
744247-56-1P 744247-58-3P 744247-60-7P
744247-62-9P 744247-64-1P 744247-66-3P
744247-68-5P 744247-70-9P 744247-72-1P
744247-74-3P 744247-76-5P 744247-78-7P
744247-80-1P 744247-82-3P 744247-84-5P
744247-86-7P 744247-88-9P 744247-91-4P
744247-94-7P 744247-97-0P 744248-00-8P
744248-03-1P 744248-06-4P 744248-09-7P
744248-12-2P 744248-15-5P 744248-18-8P
744248-20-2P 744248-22-4P 744248-24-6P
744248-26-8P 744248-28-0P 744248-30-4P
744248-32-6P 744248-34-8P 744248-36-0P
744248-38-2P 744248-40-6P 744248-42-8P
744248-44-0P 744248-45-1P 744248-46-2P
744248-47-3P 744248-48-4P 744248-49-5P
744248-50-8P 744248-52-0P 744248-53-1P
744248-55-3P 744248-58-6P 744248-59-7P
744248-60-0P 744248-67-7P 744248-68-8P
744248-69-9P 744248-70-2P 744248-71-3P
744248-72-4P 744248-73-5P 744248-74-6P
744248-75-7P 744248-76-8P 744248-77-9P
744248-78-0P 744248-79-1P 744248-80-4P
744248-81-5P 744248-82-6P 744248-83-7P
744248-84-8P 744248-85-9P 744248-86-0P
744248-87-1P 744248-88-2P 744248-89-3P
744248-90-6P 744248-91-7P 744248-92-8P
744248-93-9P 744248-94-0P 744248-95-1P
744248-96-2P 744248-97-3P 744249-00-1P
744249-04-5P 744249-07-8P 744249-11-4P

L16 ANSWER 1 OF 2 USPATFULL on STN (Continued)
744249-14-7P 744249-16-9P 744249-19-2P
744249-22-7P 744249-24-9P 744249-26-1P
744249-27-2P 744249-33-0P 744249-34-1P
744249-35-2P 744249-36-3P 744249-37-4P
744249-38-5P 744249-39-6P 744249-40-9P
744249-41-0P 744249-42-1P 744249-43-2P
744249-44-3P 744249-45-4P 744249-46-5P
744249-47-6P 744249-48-7P 744249-49-8P
744249-50-1P 744249-51-2P 744249-52-3P
744249-53-4P 744249-54-5P 744249-55-6P
744249-56-7P 744249-57-8P 744249-58-9P
744249-59-0P 744249-60-3P 744249-61-4P
744249-62-5P 744249-63-6P 744249-64-7P
744249-65-8P 744249-66-9P 744249-67-0P
744249-68-1P 744249-69-2P 744249-70-5P
744249-71-6P 744249-72-7P 744249-73-8P
744249-74-9P 744249-75-0P 744249-76-1P
744249-77-2P 744249-78-3P 744249-84-1P
744249-85-2P 744249-86-3P 744249-87-4P
744249-88-5P 744249-89-6P 744249-90-9P
744249-91-0P 744249-92-1P 744249-93-2P
744249-94-3P 744249-95-4P 744249-96-5P
744249-97-6P 744249-98-7P 744249-99-8P
744250-00-8P 744250-01-9P 744250-02-0P
744250-03-1P 744250-04-2P 744250-05-3P
744250-06-4P 744250-07-5P 744250-08-6P
744250-09-7P 744250-10-0P 744250-11-1P
744250-12-2P 744250-13-3P 744250-14-4P
744250-15-5P 744250-16-6P 744250-17-7P
744250-18-8P 744250-19-9P 744250-20-2P
744250-21-3P 744250-22-4P 744250-23-5P
744250-24-6P 744250-25-7P 744250-26-8P
744250-27-9P 744250-28-0P 744250-29-1P
744250-30-4P 744250-31-5P 744250-32-6P
744250-33-7P 744250-34-8P 744250-35-9P
744250-36-0P 744250-37-1P 744250-38-2P
744250-39-3P 744250-40-6P 744250-41-7P
744250-42-8P 744250-43-9P 744250-44-0P
744250-45-1P 744250-46-2P 744250-47-3P
744250-48-4P 744250-49-5P 744250-50-8P
744250-51-9P 744250-52-0P 744250-53-1P
744250-54-2P 744250-55-3P 744250-56-4P
744250-57-5P 744250-58-6P
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease N53 inhibitors)
IT 744250-59-7P 744250-60-0P 744250-61-1P
744250-62-2P 744250-63-3P 744250-64-4P
744250-65-5P 744250-66-6P 744250-67-7P
745013-11-0P 746657-33-0P 746657-34-1P
746657-35-2P 858948-81-9P 858948-82-0P
858948-83-1P 858948-84-2P 858948-85-3P
858948-86-4P 858948-87-5P 858948-88-6P
858948-89-7P 858948-90-0P 858948-91-1P
858948-92-2P 858948-93-3P 858948-94-4P
858948-95-5P 858948-96-6P 858948-97-7P
858948-98-8P 858948-99-9P 858949-00-5P
858949-01-6P 858949-02-7P 858949-03-8P
858949-04-9P 858949-05-0P 858949-06-1P
858949-07-2P 858949-08-3P 858949-09-4P
858949-10-7P 858949-11-8P 858949-12-9P
858949-13-0P 858949-14-1P 858949-15-2P
858949-16-3P 858949-17-4P 858949-18-5P
858949-19-6P 858949-20-9P 858949-21-0P
858949-22-1P 858949-23-2P 858949-24-3P
858949-25-4P 858949-26-5P 858949-27-6P
858949-28-7P 858949-29-8P 858949-30-1P
858949-31-2P 858949-32-3P 858949-33-4P
858949-34-5P 858949-35-6P 858949-36-7P
858949-37-8P 858949-38-9P 858949-39-0P
858949-40-3P 858949-41-4P 858949-42-5P

L16 ANSWER 1 OF 2 USPATFULL on STN (Continued)
858949-43-6P 858949-44-7P 858949-45-8P
858949-46-9P 858949-47-0P 858949-48-1P
858949-49-2P 858949-50-5P 858949-53-8P
858949-54-9P 858949-55-0P 858949-56-1P
858949-57-2P 858949-58-3P 858949-59-4P
858949-60-7P 858949-61-8P 858949-62-9P
858949-63-0P 858949-64-1P 858949-66-3P
858949-67-4P 858949-68-5P 858949-69-6P
858949-70-9P 858949-71-0P 858949-72-1P
858949-73-2P 858949-74-3P 858949-75-4P
858949-76-5P 858949-77-6P 858949-78-7P
858949-79-8P 858949-80-1P 858949-81-2P
858949-82-3P 858949-83-4P 858949-84-5P
858949-85-6P 858949-86-7P 858949-87-8P
858949-88-9P 858949-89-0P 858949-90-3P
858949-91-4P 858949-92-5P 858949-93-6P
858949-96-9P 858949-97-0P 858949-98-1P
858949-99-2P 858950-00-2P 858950-01-3P
858950-02-4P 858950-03-5P 858950-04-6P
858950-05-7P 858950-06-8P 858950-07-9P
858950-08-0P 858950-09-1P 858950-10-4P
858950-11-5P 858950-12-6P 858950-13-7P
858950-14-8P 858950-15-9P 858950-16-0P
858950-17-1P 858950-18-2P 858950-19-3P
858950-20-6P 858950-21-7P 858950-22-8P
858950-23-9P 858950-24-0P 858950-25-1P
858950-26-2P 858950-27-3P 858950-28-4P
858950-29-5P 858950-30-8P 858950-31-9P
858950-32-0P 858950-33-1P 858950-35-3P
858950-37-5P 858950-39-7P 858950-41-1P
858950-42-2P 858950-45-5P 858950-57-9P
858950-58-0P 858950-59-1P 858950-60-4P
858950-61-5P 858950-63-7P 858950-65-9P
858950-66-0P 858950-67-1P 858950-68-2P
858950-69-3P 858950-70-6P 858950-71-7P
858950-72-8P 858950-73-9P 858950-74-0P
858950-75-1P 858950-76-2P 858950-77-3P
858950-78-4P 858950-79-5P 858950-80-8P
858950-81-9P 858950-82-0P 858950-83-1P
858950-84-2P 858950-85-3P 858950-86-4P
858950-87-5P 858950-88-6P 858950-89-7P
858950-90-0P 858950-91-1P 858950-92-2P
858950-93-3P 858950-94-4P 858950-95-5P
858950-96-6P 858950-97-7P 858950-98-8P
858950-99-9P 858951-00-5P 858951-01-6P
858951-02-7P 858951-03-8P 858951-04-9P
858951-05-0P 858951-06-1P 858951-07-2P
858951-08-3P 858951-10-7P 858951-12-9P
858951-13-0P 858951-14-1P 858951-15-2P
858951-16-3P 858951-17-4P 858951-18-5P
858951-19-6P 858951-20-9P 858951-21-0P
858951-22-1P 858951-23-2P 858951-24-3P
858951-25-4P 858951-26-5P
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease N53 inhibitors)
IT 858951-27-6P 858951-28-7P 858951-29-8P
858951-30-1P 858951-31-2P 858951-32-3P
858951-33-4P 858951-34-5P 858951-35-6P
858951-36-7P 858951-37-8P 858951-38-9P
858951-39-0P 858951-40-3P 858951-41-4P
858951-42-5P 858951-43-6P 858951-44-7P
858951-45-8P 858951-46-9P 858951-47-0P
858951-48-1P 858951-49-2P 858951-50-5P
858951-51-6P 858951-52-7P 858951-53-8P
858951-54-9P 858951-55-0P 858951-56-1P
858951-57-2P 858951-58-3P 858951-59-4P
858951-60-7P 858951-61-8P 858951-62-9P
858951-63-0P 858951-64-1P 858951-65-2P
858951-66-3P 858951-67-4P 858951-68-5P
858951-70-9P 858951-71-0P 858951-72-1P
858951-73-2P 858951-74-3P 858951-75-4P
858951-76-5P 858951-77-6P 858951-78-7P
858951-79-8P 858951-80-1P 858951-81-2P
858951-82-3P 858951-83-4P 858951-84-5P

L16 ANSWER 1 OF 2 USPATFULL on STN (Continued)
858951-85-6P 858951-86-7P 858951-87-8P
858951-88-9P 858951-89-0P 858951-90-3P
858951-91-4P 858951-92-5P 858951-93-6P
858951-94-7P 858972-57-3P 858972-58-4P
858972-62-0P 858972-63-1P 858972-64-2P
858972-68-6P 858972-69-7P 858972-70-0P
858972-74-4P
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease N53 inhibitors)
IT 744251-08-9P 744251-12-5P 744251-15-8P
744251-18-1P 744251-21-6P 744251-25-0P
744251-32-9P 744251-33-0P 744251-47-6P
744251-51-2P 744251-52-3P
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease N53 inhibitors)
IT 744247-19-6P
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease N53 inhibitors)
RN 744247-19-6 USPATFULL
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(5-phenyl-2H-tetrazol-2-yl)-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)



L16 ANSWER 2 OF 2 USPATFULL on STN

AN 2004:233741 USPATFULL

TI Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors

IN Nakajima, Suanne, Cambridge, MA, UNITED STATES
Tang, Datong, Malden, MA, UNITED STATES
Wu, Frank, Shrewsbury, MA, UNITED STATES
Miao, Zhenwei, Medway, MA, UNITED STATES
Sun, Ying, Waltham, MA, UNITED STATES
Or, Yat Sun, Watertown, MA, UNITED STATES
Wang, Zhe, Hockessin, DE, UNITED STATES

PI US-20040180815 A1 20040916

AI 2003US-000384120 A1 20030307 (10)

DT Utility

FS APPLICATION

LREP ENANTA PHARMACEUTICALS, INC., ATTN: PATENT DEPT., 500 ARSENAL STREET, WATERTOWN, MA, 02472

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2590

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR1##

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 744247-19-6P 744247-22-1P 744247-24-3P
744247-26-5P 744247-28-7P 744247-30-1P
744247-32-3P 744247-34-5P 744247-36-7P
744247-38-9P 744247-40-3P 744247-42-5P
744247-44-7P 744247-46-9P 744247-48-1P
744247-50-5P 744247-52-7P 744247-54-9P
744247-56-1P 744247-58-3P 744247-60-7P
744247-62-9P 744247-64-1P 744247-66-3P
744247-68-5P 744247-70-9P 744247-72-1P
744247-74-3P 744247-76-5P 744247-78-7P
744247-80-1P 744247-82-3P 744247-84-5P
744247-86-7P 744247-88-9P 744247-91-4P
744247-94-7P 744247-97-0P 744248-00-8P
744248-03-1P 744248-06-4P 744248-09-7P
744248-12-2P 744248-15-5P 744248-18-8P
744248-20-2P 744248-22-4P 744248-24-6P
744248-26-8P 744248-28-0P 744248-30-4P
744248-32-6P 744248-34-8P 744248-36-0P
744248-38-2P 744248-40-6P 744248-42-8P
744248-44-0P 744248-45-1P 744248-46-2P
744248-47-3P 744248-48-4P 744248-49-5P
744248-50-8P 744248-52-0P 744248-53-1P
744248-55-3P 744248-58-6P 744248-59-7P
744248-60-0P 744248-67-7P 744248-68-8P
744248-69-9P 744248-70-2P 744248-71-3P
744248-72-4P 744248-73-5P 744248-74-6P
744248-75-7P 744248-76-8P 744248-77-9P
744248-78-0P 744248-79-1P 744248-80-4P
744248-81-5P 744248-82-6P 744248-83-7P
744248-84-8P 744248-85-9P 744248-86-0P
744248-87-1P 744248-88-2P 744248-89-3P
744248-90-6P 744248-91-7P 744248-92-8P
744248-93-9P 744248-94-0P 744248-95-1P
744248-96-2P 744248-97-3P 744249-00-1P
744249-04-5P 744249-07-8P 744249-11-4P
744249-14-7P 744249-16-9P 744249-19-2P

L16 ANSWER 2 OF 2 USPATFULL on STN (Continued)



L16 ANSWER 2 OF 2 USPATFULL on STN (Continued)

744249-22-7P 744249-24-9P 744249-26-1P
744249-27-2P 744249-33-0P 744249-34-1P
744249-35-2P 744249-36-3P 744249-37-4P
744249-38-5P 744249-39-6P 744249-40-9P
744249-41-0P 744249-42-1P 744249-43-2P
744249-44-3P 744249-45-4P 744249-46-5P
744249-47-6P 744249-48-7P 744249-49-8P
744249-50-1P 744249-51-2P 744249-52-3P
744249-53-4P 744249-54-5P 744249-55-6P
744249-56-7P 744249-57-8P 744249-58-9P
744249-59-0P 744249-60-3P 744249-61-4P
744249-62-5P 744249-63-6P 744249-64-7P
744249-65-8P 744249-66-9P 744249-67-0P
744249-68-1P 744249-69-2P 744249-70-5P
744249-71-6P 744249-72-7P 744249-73-8P
744249-74-9P 744249-75-0P 744249-76-1P
744249-77-2P 744249-78-3P 744249-84-1P
744249-85-2P 744249-86-3P 744249-87-4P
744249-88-5P 744249-89-6P 744249-90-9P
744249-91-0P 744249-92-1P 744249-93-2P
744249-94-3P 744249-95-4P 744249-96-5P
744249-97-6P 744249-98-7P 744249-99-8P
744250-00-8P 744250-01-9P 744250-02-0P
744250-03-1P 744250-04-2P 744250-05-3P
744250-06-4P 744250-07-5P 744250-08-6P
744250-09-7P 744250-10-0P 744250-11-1P
744250-12-2P 744250-13-3P 744250-14-4P
744250-15-5P 744250-16-6P 744250-17-7P
744250-18-8P 744250-19-9P 744250-20-2P
744250-21-3P 744250-22-4P 744250-23-5P
744250-24-6P 744250-25-7P 744250-26-8P
744250-27-9P 744250-28-0P 744250-29-1P
744250-30-4P 744250-31-5P 744250-32-6P
744250-33-7P 744250-34-8P 744250-35-9P
744250-36-0P 744250-37-1P 744250-38-2P
744250-39-3P 744250-40-6P 744250-41-7P
744250-42-8P 744250-43-9P 744250-44-0P
744250-45-1P 744250-46-2P 744250-47-3P
744250-48-4P 744250-49-5P 744250-50-8P
744250-51-9P 744250-52-0P 744250-53-1P
744250-54-2P 744250-55-3P 744250-56-4P
744250-57-5P 744250-58-6P
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)

IT 744250-59-7P 744250-60-0P 744250-61-1P
744250-62-2P 744250-63-3P 744250-64-4P
744250-65-5P 744250-66-6P 744250-67-7P
745013-11-0P 746657-33-0P 746657-34-1P
746657-35-2P
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)

IT 744251-08-9P 744251-12-5P 744251-15-8P
744251-18-1P 744251-21-6P 744251-25-0P
744251-32-9P 744251-33-0P 744251-47-6P
744251-51-2P 744251-52-3P
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)

IT 744247-19-6P
(macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)

RN 744247-19-6 USPATFULL

CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-5,16-dioxo-2-(5-phenyl-2H-tetrazol-2-yl)-, (2R,6S,13aS,14aR,16aS)- (CA INDEX NAME)

```
=> d his

     (FILE 'HOME' ENTERED AT 17:08:34 ON 12 MAR 2008)

     FILE 'HCAPLUS' ENTERED AT 17:08:49 ON 12 MAR 2008
L1             1 US20050153877/PN

     FILE 'REGISTRY' ENTERED AT 17:09:01 ON 12 MAR 2008

     FILE 'HCAPLUS' ENTERED AT 17:09:01 ON 12 MAR 2008
L2             TRA L1 1- RN :      730 TERMS

     FILE 'REGISTRY' ENTERED AT 17:09:01 ON 12 MAR 2008
L3           730 SEA L2
L4           588 L3 AND NRRS>=3
L5               STR
L6            40 L5
L7           763 L5 FULL
                 SAV TEM J047C1G1/A L7
L8           553 L7 AND L3
L9           210 L7 NOT L8

     FILE 'HCAPLUS' ENTERED AT 17:25:28 ON 12 MAR 2008
L10            4 L8
L11            4 L9
L12            2 L10 AND L11
L13            2 L11 NOT L12
L14            4 L10,L12

     FILE 'HCAOLD' ENTERED AT 17:29:44 ON 12 MAR 2008
L15            0 L7

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:29:54 ON 12 MAR 2008
L16            2 L7

=>
```